Phil Ferneau

Phil has led the firm’s healthcare investing from its inception. He currently leads Borealis’ investments in Adimab, Amagma, Avitide, Compass Therapeutics, Evox Therapeutics, Orbit Discovery, Ovation.io, T-Cypher Bio, and Teckro. Phil also led the firm’s prior investments in Avedro (Nasdaq: AVDR), GlycoFi (acquired by Merck & Co.), M2S (acquired by AIG Altaris Health Partners), and Vets First Choice (Nasdaq: CVET).

In addition to his Borealis investing, Phil has spent over 20 years advancing innovation ecosystems at Dartmouth College and other universities. Phil joined Borealis from Dartmouth’s Tuck School of Business, where he was the founding Executive Director of the Center for Private Equity and Entrepreneurship. Phil remains an adjunct member of Tuck’s faculty teaching venture capital topics. He was previously a trustee of the Dartmouth Regional Technology Center.

Phil began his career in private legal practice, counseling technology startups, Fortune 500 companies, and foreign governments on sensitive trade, tax, and investment matters.

Phil received an A.B. degree from Dartmouth College, a J.D. from the University of Virginia School of Law, and a M.B.A. (with High Distinction) from the Tuck School of Business at Dartmouth.